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Abstract
Two classes of antiviral drugs, neuraminidase inhibitors and adamantanes, are approved for prophylaxis and therapy against
influenza virus infections. A major concern is that antiviral resistant viruses emerge and spread in the human population.
The 2009 pandemic H1N1 virus is already resistant to adamantanes. Recently, a novel neuraminidase inhibitor resistance
mutation I223R was identified in the neuraminidase of this subtype. To understand the resistance mechanism of this
mutation, the enzymatic properties of the I223R mutant, together with the most frequently observed resistance mutation,
H275Y, and the double mutant I223R/H275Y were compared. Relative to wild type, KM values for MUNANA increased only 2-
fold for the single I223R mutant and up to 8-fold for the double mutant. Oseltamivir inhibition constants (KI) increased 48-
fold in the single I223R mutant and 7500-fold in the double mutant. In both cases the change was largely accounted for by
an increased dissociation rate constant for oseltamivir, but the inhibition constants for zanamivir were less increased. We
have used X-ray crystallography to better understand the effect of mutation I223R on drug binding. We find that there is
shrinkage of a hydrophobic pocket in the active site as a result of the I223R change. Furthermore, R223 interacts with S247
which changes the rotamer it adopts and, consequently, binding of the pentoxyl substituent of oseltamivir is not as
favorable as in the wild type. However, the polar glycerol substituent present in zanamivir, which mimics the natural
substrate, is accommodated in the I223R mutant structure in a similar way to wild type, thus explaining the kinetic data. Our
structural data also show that, in contrast to a recently reported structure, the active site of 2009 pandemic neuraminidase
can adopt an open conformation.
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Introduction
Strategies to combat the burden of disease caused by influenza
mainly rely on vaccination [1]. However, in cases when vaccine
efficacy is low or vaccine is unavailable, for instance during the first
months of a pandemic, antiviral drugs are an important line of
defense. For individual patients, especially when the immune system
is compromised, antiviral therapy may be life saving [2]. Tradition-
ally, both the adamantane and neuraminidase inhibitor class of drugs
have been available for prophylaxis and therapy. However, the
majority of recently circulating influenza viruses are resistant to the
adamantanes, including the A/H1N1 2009 pandemic influenza virus
[3]. This leaves neuraminidase inhibitors (NAIs) as the only option.
Stimulated by the first neuraminidase (NA) crystal structures, the
NAIs were designed to interact with the active site of all NA types
[4,5]. Because the NA active site is highly conserved, resistant mutants
with amino acid changes in the proximity of this active site, were
considered likely to be enzymatically compromised and thus predicted
to be of marginal epidemiological and clinical significance [6]. Indeed,
the first viruses identified as harboring NAI resistant mutations were
compromised in their replicative capacity and transmissibility [7–9].
Nevertheless, a novel oseltamivir-resistant influenza A/H1N1 variant
emerged in the 2007–2008 influenza season and became the
dominant virus in some parts of the world [10,11]. Resistance to
oseltamivir was caused by a previously identified, and frequently
observed, histidine to tyrosine change in the NA at position 275
(H275Y). In contrast to earlier observations on H275Y mutants, this
change did not compromise viral replication or transmissibility in the
background of the 2007–2008 H1N1 virus [12–14]. Additional
mutations in the NA were identified that explained why this resistant
virus was able to emerge and become widespread [15,16].
With the 2009 pandemic, a novel influenza A/H1N1 virus was
introduced into the human population [17]. Given that the
appearance of NAI drug resistant mutations varies with the type
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and structure of the neuraminidase that the virus carries, we were
interested to identify and characterize novel patterns of resistance
in this virus. We identified a novel isoleucine to arginine change at
position 223 (I223R) in the NA of a virus isolated from an immune
suppressed child on prolonged oseltamivir and zanamivir therapy
[18]. In contrast to the frequently observed H275Y change, which
causes selective resistance to oseltamivir, the I223R mutation
conferred a resistance phenotype against both oseltamivir and
zanamivir. Soon after the identification of this first clinical case,
the I223R change was found as a single change or in combination
with H275Y, in a number of other cases [19,20]. The I223R/
H275Y double mutant proved to have high levels of resistance to
oseltamivir. Both in vitro studies and in animal models, viruses with
I223R and the combination of I223R with H275Y were found not
to be compromised in their replication capacity or transmissibility
[21,22].
The structural basis of resistance conferred by the H275Y has
been described previously [23]. Here we address the role of the
I223R in NAI resistance alone and in combination with H275Y.
Both I223R and H275Y changes are near the active site of A/
H1N1 pandemic NA. Previously, it was shown that different NA
sub types (N1–N9) can be grouped into two genetically distinct
groups [24]. The active sites of group-1 NAs (N1, N4, N5, N8)
have an extra cavity when crystallized in the absence of inhibitor,
because of the ‘open’ conformation of an active site loop, the 150-
loop. This loop, containing residues 148–151, closes a cavity
adjacent to the active site upon drug binding (150-cavity). In
contrast, in group-2 (N2, N3, N6, N7, N9) NA, this loop adopts
the closed conformation in the presence or absence of active site
ligands. Recently however, a crystal structure for a ligand-free
form of the H1N1 pandemic NA was reported, which showed the
active site in a closed conformation [25]. More recently, NMR
studies on the pandemic neuraminidase have considered this
difference and suggested that the neuraminidase prefers to adopt
an open conformation [26]. Our results support this suggestion by
indicating that a ligand-free form of the pandemic neuraminidase
adopts an open conformation. Together with this structure we
present the structures of the I223R mutant neuraminidase in
complex with oseltamivir and zanamivir to investigate the
resistance mechanism of the I223R mutant neuraminidase. We
interpret our results of enzyme kinetic measurements in relation to
the structures of the complexes.
Results/Discussion
The NA studied here originated from a pandemic influenza A/
H1N1 virus which was isolated from an immune suppressed child
on oseltamivir and intravenously (IV) administered zanamivir
antiviral therapy. It contained the mutation I223R [18]. Since this
change has been reported both as a single mutation as well as in
combination with the substitution H275Y [19], virus recombinants
were constructed containing the wild type NA, the I223R or
H275Y single mutants and the I223R, H275Y double mutant.
Enzyme kinetics of the I223R and H275Y mutant
neuraminidases
To study the effects of the single mutations I223R and H275Y,
and the double mutant on the enzymatic properties of NA,
Michaelis-Menten (KM) constants were determined using MU-
NANA as a substrate. Relative to wild type NA, KM values
increased marginally for the I223R and H275Y single mutants.
There was a maximum 8-fold increase for the double mutant
(Table 1). In the 2007–2008 influenza H1N1 season, naturally
occurring H275Y variants had emerged, which were not
attenuated in virus growth or transmissibility. Our observations
suggest that, as was observed with the non-attenuated H275Y
variants in the 2007–2008 season, the occurrence of viable NAI
resistant pandemic influenza A/H1N1 viruses is not an unlikely
event.
The sensitivity to oseltamivir and zanamivir was determined for
the single and double mutants. By comparison to the oseltamivir
inhibitor constant (KI) of wild type NA, the KI of the I223R
mutant increased 48 times and the I223R/H275Y double mutant
KI more than 7500 times. The change in the KI for I223R (48-
fold) was largely accounted for by an increased dissociation rate
constant for the enzyme-inhibitor complex (15-fold) rather than by
a reduced association rate constant (kon) (3-fold). In the case of
zanamivir, the KI increased 9-fold for the single and 22-fold for
the double mutant relative to wild type. The change in the KI for
I223R (9-fold) was in this case accounted for by a reduced
association rate constant (4-fold) and a slightly increased dissoci-
ation rate constant (2-fold). Thus the I223R mutation has a
markedly greater effect on NA inhibition by oseltamivir than by
zanamivir.
Although the KM-values for MUNANA are increased about
equally for both the I223R and H275Y single mutants, the change
in oseltamivir inhibitor constant for the H275Y mutant relative to
wild type, is approximately 10 times greater than for the I223R
mutant (Table 1). This may explain why the H275Y change may
be the more likely resistance change in oseltamivir monotherapy
and of course, to date, the H275Y mutation is the most frequently
detected oseltamivir resistance mutation.
The active site of the H1N1 pandemic neuraminidase has
an open conformation
Crystals of wild type and mutant neuraminidases were grown in
the absence or presence of the oseltamivir and zanamivir
neuraminidase inhibitors. The crystals yielded high-resolution
diffraction data and the structures were solved by molecular
replacement and refined by standard procedures (Table 2.) The
first striking feature from these data is that the 150-loop in the
Author Summary
Recently, a pandemic A/H1N1 influenza virus was isolated
from an immune compromised patient with a novel
antiviral resistance pattern to the neuraminidase inhibitor
class of drugs. This virus had an amino acid change in the
viral neuraminidase enzyme; an isoleucine at position 223
was substituted by an arginine (I223R). Patients infected
with such a virus leave physicians with reduced antiviral
treatment options, since pandemic viruses are naturally
resistant to the other class of antivirals, the adamantanes.
Previously, we have shown that this mutant virus retains its
potential to cause disease and may still be able to spread
in the human population.
Here we used enzyme kinetic measurements and crystal
structures of the I223R mutant neuraminidase to deter-
mine the resistance mechanism of this amino acid change.
We found that the I223R change results in shrinkage of the
active site of the enzyme. As a result, binding of the
neuraminidase inhibitors is affected. In addition, we found
that the active site of our pandemic neuraminidase
structure, crystallized in the absence of inhibitor, has an
extra cavity (150-cavity) adjacent to the active site. Our
study could aid in the development of novel inhibitors
designed to target the 150-cavity and active site of the
enzyme.
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Table 1. Kinetic parameters and oseltamivir/zanamivir drug binding for 2009 pandemic influenza A/H1N1 neuraminidase mutants.
Oseltamivir Zanamivir
Virus PDB ID KM
* KI (nM) kon (mM
21 s21) 1036koff (s
21) Ki (nM) kon (mM
21 s21) 1036koff (s
21)
Wild type 4B7Q/4B7R 1.0 0.23 (0.12) 3.10 (0.12) 0.75 (0.20) 0.18 (0.03) 1.31 (0.15) 0.32 (0.10)
I223R 4B7M/4B7J/4B7N 2.1 11.1 (1.10) 1.04 (0.09) 11.1 (0.90) 1.65 (0.40) 0.36 (0.12) 0.78 (0.12)
H275Y ND** 2.6 145 (32) ND ND 0.53 (0.06) 1.02 (0.04) 0.76 (0.21)
I223R/H275Y ND 8.1 1750 (150) ND ND 3.92 (0.15) 0.15 (0.01) 0.72 (0.24)
Measurements were performed in triplicate and values in parentheses are standard deviations from the mean.
*KM values presented relative to wild type.
KM value for wild type = 28.0 mM.
**ND = Not determined.
doi:10.1371/journal.ppat.1002914.t001
Table 2. Data collection and refinement statistics.
Virus NL2631 NL2631 NL2631 Cal07 Cal07
NAI - Oseltamivir Zanamivir Oseltamivir Zanamivir
PDB ID code 4B7M 4B7J 4B7N 4B7R 4B7Q
Amino acid differences* V106I, I223R, N248D V106I, I223R, N248D V106I, I223R, N248D - -
Data Collection
Wavelength (A˚) 0.9173 0.9763 0.97625 0.97950 0.97630
Space group C2221 P4212 P4212 P212121 P212121
Cell dimensions
a, b, c (A˚) 118.6, 162.5, 118.9 118.6, 118.6, 67.8 118.4, 118.4, 68.4 83.4, 149.0, 166.8 82.7, 148.8, 166.6
a, b, c (u) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (A˚) 30.0-2.5 (2.61-2.50) 83.8-2.4 (2.55-2.42) 83.7-2.84 (3.00-2.84) 30.0-1.90 (1.99-1.90) 82.65-2.73 (2.80-2.73)
Rmerge 14.2 (60.8) 13.0 (41.6) 15.7 (48.1) 12.5 (72.8) 20.5 (53.8)
I/sI 9.3 (2.1) 11.4 (4.5) 15.3 (6.0) 13.5 (3.0) 6.1 (2.5)
Completeness (%) 93.3 (92.0) 100 (100) 100 (100) 99.7 (98.0) 99.2 (99.0)
Multiplicity 5.6 (4.6) 10.8 (10.5) 13.3 (13.3) 6.4 (4.8) 6.8 (6.4)
Unique reflections 37388 19102 11923 163254 55091
Refinement
Resolution (A˚) 95.8-2.5 84-2.42 83.6-2.84 111-1.9 82.6-2.7
No. reflections 27395 17197 11333 154943 52204
Rwork/Rfree 20.5/23.7 22.8/27.6 18.5/22.4 18.4/20.4 22.4/27.1
Rfree test set size (%) 4.9 5.1 4.8 5.0 5.1
Rfree test set count 1412 931 567 8190 2790
No. atoms 6367 3196 3179 13079 12721
B-factor 16.5 13.1 12.7 28.6 35
R.m.s deviations
Bond lengths (A˚) 0.007 0.005 0.006 0.007 0.0054
Bond angles (u) 1.437 0.995 1.037 1.281 0.9922
MolProbity
MolProbity, clash score 0.16 (100th percentile) 0.33 (100th percentile) 0.65 (100th percentile) 0.08 (100th percentile) 0.33 (100th percentile)
MolProbity score 1.00 (100th percentile) 1.01 (100th percentile) 1.09 (100th percentile) 0.76 (100th percentile) 1.07 (100th percentile)
Ramachandran favored (%) 95.6 95.32 96.35 96.49 95.26
Residues with bad bonds (%) 0.0 0.78 0.0 0.0 0.0
Residues with bad angles (%) 0.0 0.26 0.0 0.0 0.06
*Amino acid differences as compared to Cal07.
doi:10.1371/journal.ppat.1002914.t002
Resistance Mechanism of the I223R Change
PLOS Pathogens | www.plospathogens.org 3 September 2012 | Volume 8 | Issue 9 | e1002914
ligand-free I223R NA adopts an open conformation, as seen in the
first reported N1 structure [24], but in contrast to the closed
conformation of this loop seen in the recently reported crystal
structure of the 2009 pandemic A/H1N1 NA (Figure 1A) [25].
Recent NMR experiments likely clarify the apparent discrepancy
in these different studies by showing that the 150-loop is flexible
and that an equilibrium between the open and closed conforma-
tions exists in solution [26]. Inspection of our current structure
shows that a phosphate ion, from the crystallization buffer,
interacts with lysine 150 to stabilize the open conformation. We
speculate that the different crystallization conditions used in the
previous pandemic N1 study led to the stabilization of the closed
Figure 1. Crystal structures of H1N1 2009 pandemic neuraminidase reveal the open conformational state of its active site. Panel A
presents the active site of a 2009 pandemic neuraminidase (PDB ID code 4B7M) in an open conformation. This is the preferred state in the absence of
neuraminidase inhibitor. When a protein/inhibitor complex is formed, a flexible loop (150-loop) closes the 150-cavity (panel B). Both the open and
closed neuraminidase structures lack a smaller cavity near position 223, due to an isoleucine to arginine change (I223R). This pocket is still present in
the wild type N1 neuraminidase (PDB ID code 2HTY [24]) structure of H5N1 (panel C). Further narrowing of the active site by the I223R change causes
antiviral resistance to both oseltamivir and zanamivir. In panel D, an overlay of the 150-loop is presented showing important amino acids in close
proximity to the active site. An aspartic acid D151 in the 150-loop and arginine R152 in the 150-loop make hydrogen bond contacts with oseltamivir
(or zanamivir) and stabilize the closed conformation of the neuraminidase.
doi:10.1371/journal.ppat.1002914.g001
Resistance Mechanism of the I223R Change
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form [25]. The exact function of the open 150-loop in group-1
neuraminidases is unknown, but opening and closing of the loop
may have evolved for natural sialo-glycan substrates to fit into the
active site. The open conformation of the 150-loop (residues 148–
151) generates an additional cavity at the edge of the active site
that we have previously called the 150-cavity (Figure 1A), which
we have suggested to be an additional target site for neuraminidase
inhibitor design [24,27].
Changes in oseltamivir binding by the I223R change
In the wild type N1 neuraminidase structure, a small pocket, the
‘‘223-pocket’’ (Figure 1C), also adjacent to the active site, but
distinct from the 150-cavity, contains two water molecules. In the
I223R neuraminidase, this pocket is occupied by the side chain of
R223. In displacing the two water molecules seen in the wild-type
structure, the arginine makes a hydrogen bond with the side chain
of serine 247 (S247). As a result, the side chain of S247 adopts a
different rotamer and is oriented towards the active site which
enables it to make a second hydrogen bond with glutamic acid 277
(E277). These changes in the structure of the I223R neuramin-
idase result in shrinkage at the edge of the active site pocket that
accommodates the hydrophobic pentoxyl group of oseltamivir.
Thus, oseltamivir binding to the active site of I223R neuramin-
idase requires the reorientation of the S247 and R223 side chains.
Moreover, the reorientation of the side-chain of E277, which is
required for oseltamivir binding to wild-type neuraminidase, is
presumably made even less energetically favorable in the I223R
mutant by the need to disrupt the hydrogen bond between S247
and E277. Thus the binding of oseltamivir to the active site of the
I223R mutant results not only in changes in the conformation of
the side chain of S247 but also in the side-chain of R223 being
translated about 1.1 A˚ out of the active site compared to the
mutant ligand-free structure (Figure 2A).
S247 therefore plays an important role in the decreased
sensitivity of the I223R neuraminidase to inhibitors. Interestingly,
a serine to asparagine change at position 247 (S247N) has also
been linked to oseltamivir resistance [28]. Like the I223R change,
the S247N mutation also causes enhanced resistance to oseltamivir
when accompanied by the H275Y change. Both the single and the
S247N/H275Y double mutant viruses were found not to be
compromised in a ferret model suggesting that the mutant
neuraminidases retain most of their normal activity [29]. An
asparagine at position 247, an amino acid with a larger polar side
chain, can also affect the size of the hydrophobic pocket.
Therefore, although there is no structural information in that
case we speculate that, like the I223R change, the resistance
mechanism of the S247N change also may involve shrinkage of the
hydrophobic pocket.
Figure 2. Antiviral resistance mechanism of the I223R mutant. In panel A, an overlay of three pandemic neuraminidase structures is
presented: I223R mutant ligand-free structure (blue, NL2631, PDB ID code 4B7M) and both wild type (green, Cal07, PDB ID code 4B7R) and I223R
mutant (white, Cal07, PDB ID code 4B7J) oseltamivir complexes. The key amino acid residues involved in I223R antiviral resistance pattern are
displayed. Binding of oseltamivir to the active site is inhibited by arginine 223 (R223) and serine 247 (S247). The side chain of S247 points towards the
active site in the I223 mutant. Oseltamivir binding to the I223R mutant involves reorientation of both R223 and S247 residues. In panel B, an overlay is
presented of an H275Y mutant neuraminidase structure in complex with oseltamivir (yellow, VN04, PDB ID code 2CL0 [23]) with two I223R mutant
neuraminidase crystal structures: The ligand-free structure (blue, NL2631, PDB ID code 4B7M) and the structure in complex with oseltamivir (green,
NL2631, PDB ID code 4B7J). The resistance mechanisms of the H275Y and I223R mutants act synergistically to gain enhanced levels of oseltamivir
resistance.
doi:10.1371/journal.ppat.1002914.g002
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Structural changes in the I223R/H275Y double mutant
The mechanism whereby the H275Y mutant neuraminidase
binds substantially more weakly to oseltamivir than wild type has
been described previously [23]. In brief, the introduction of the
bulkier tyrosine residue perturbs the position and the reorientation
of the acidic side chain of E277 required for oseltamivir binding,
such that the hydrophobic pentoxyl substituent of oseltamivir is
translated out of the active site towards the pocket occupied in the
I223R structure by the side chain of the arginine residue
(Figure 2B). The I223R mutation, therefore, appears to restrict
the alternative position that the pentoxyl substituent adopts in the
H275Y mutant. Furthermore, the binding of oseltamivir by the
I223R/H275Y double mutant becomes even less energetically
favorable than by either of the two single mutant proteins. Our
structural data therefore provide an explanation for the 1750-fold
poorer binding of oseltamivir by the I223R/H275Y double
mutant by comparison with the wild-type neuraminidase (Table 1).
The polarity of the zanamivir glycerol substituent
correlates with the smaller effect of the I223R mutation
on zanamivir binding
Our structural studies help to explain how the single I223R and
I223R/H275Y double mutant neuraminidases bind zanamivir
almost as well as wild type. Instead of the hydrophobic pentoxyl
substituent present in oseltamivir, zanamivir possesses the same
polar glycerol substituent as sialic acid (Figures 2 and 3).
Consequently, binding of zanamivir to the active site of
neuraminidase does not require the reorientation of the side chain
of E277. In the case of the wild type neuraminidase, the glycerol
moiety of zanamivir forms two hydrogen bonds with E277. This
interaction is unaffected in the H275Y mutant (Figure 3). In the
I223R single or double mutant neuraminidases, somewhat
different interactions are made by the glycerol moiety: one
hydrogen bond is formed with E277 and another hydrogen bond
is formed with S247 (Figure 3A). To facilitate zanamivir binding in
this way R223 is reoriented only marginally and it still retains the
R223 hydrogen bond with S247 (Figure 3).
The plasticity of the pandemic neuraminidase active site,
especially around the hydrophobic pocket, allows the emergence
of drug resistant influenza variants. In addition to the I223R
change, isoleucine 223 changes to valine (I223V) and lysine
(I223K) accompanying the H275Y change have also been
reported [20]. This further indicates that this residue plays an
important role in neuraminidase inhibitor resistance and stresses
the importance of a detailed understanding of the mechanism of
resistance. Since the single I223R change described here resulted
in only a 9-fold increase in the KI for zanamivir, it is interesting to
consider why the I223R mutant virus persisted in the IV
zanamivir treated immunocompromised patient. As previously
suggested [30], suboptimal drug levels in the patient’s respiratory
tract, due to the route of administration (IV versus inhaled) as well
as the immune status of the patient may have contributed to the
emergence and persistence of the I223R mutant virus.
Materials and Methods
Antiviral compounds and recombinant viruses
Hoffmann-La Roche Ltd. (Switzerland) kindly provided oselta-
mivir carboxylate. Zanamivir was kindly provided by GlaxoSmith-
Kline (the Netherlands). Recombinant influenza viruses were
generated by reverse genetics essentially as previously described
Figure 3. The polarity of zanamivir enables inhibition of the I223R mutant. In panel A, hydrogen bond contacts are presented (dotted
lines), which are formed between zanamivir and active site residues in the I223R mutant (purple, PDB ID code 4B7N). The insert displays the
interactions between the same residues in the I223R mutant ligand-free structure (blue, PDB ID code 4B7M). In panel B, active site residues and
hydrogen bonds are displayed, which are formed in the wild type zanamivir structure complex (brown, PDB ID code 4B7Q). The insert displays the
I223, S247 and E277 residues in the wild type ligand-free structure.
doi:10.1371/journal.ppat.1002914.g003
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[31]. Each virus contained seven segments of A/WSN/33 and the
neuraminidase gene of either A/Netherlands/2631_1202/2010
(NL2631), A/California/07/09 (Cal07) or A/Vietnam/1203/04
(VN04). Recombinant viruses were propagated in embryonated
chicken eggs. Allantoic fluids were harvested after 48 hrs and
cleared from debris by centrifugation at 3000 rpm for 15 minutes.
They were then used directly to measure enzyme kinetics or further
processed to purify the neuraminidase for crystallography.
Neuraminidase activity measurements
Michaelis-Menten constants (KM) were determined at 37uC as
previously described [23], using standard initial rate measure-
ments with virus diluted in 32.5 mM MES buffer (pH 6.4), 5 mM
CaCl2 and fluorescent substrate 29-(4-methylumbelliferyl1)-a-D-
N-acetylneuraminic acid (MUNANA) concentrations ranging
from 2.0 to 200 mM. Inhibition constants (KI) were determined
by following the reduction in MUNANA hydrolysis rate following
addition of inhibitor to a virus/MUNANA mixture approximately
100 s after initiation of the reaction. KI was then calculated using
equation (1) [32]:
VI~
V0(½SzKm)
½SzKm 1z ½I 
KI
  ð1Þ
where VI is the new steady state hydrolysis rate in the presence of
inhibitor at concentration [I], V0 is the rate in the absence of
inhibitor, [S] is the MUNANA concentration, KM is the
Michaelis-Menten constant and KI is the dissociation constant
for inhibitor binding. The kinetic parameters for inhibitor binding
were determined by analyzing the exponential approach to VI
using the following equation [33]:
Ft~F0zVItz(V0{VI )(1{e
{kOBSt)=kOBS ð2Þ
where F0 and Ft are the fluorescence signals at time zero and time
t, and kOBS is the first-order rate constant. Association (kon) and
dissociation (koff) rate constants for inhibitor binding were then
determined by plotting kOBS versus [I] using the following
equation [34]:
kOBS~koffz
konKm½I 
Kmz½S ð3Þ
In most cases the kinetically determined KI values (koff/kon) agree
well with those determined using equation (2). Measurements were
performed in triplicate using three different inhibitor concentrations.
Neuraminidase purification
Recombinant virus was harvested from clarified allantoic fluid
by centrifugation at 6000 rpm overnight at 4uC and resuspended
in 10 mM TRIS buffer, (pH 8.0), 150 mM NaCl (TRIS-buffer).
Virus was then layered over a continuous sucrose gradient (15–
40% sucrose in TRIS-buffer) and centrifuged at 25.000 rpm for
45 minutes at 4uC. The virus-containing fraction was collected
and virus was pelleted by dilution of the remaining sucrose with
Tris-buffer and centrifugation at 27.000 rpm for 90 minutes at
4uC. The purified virus was resuspended in Tris-buffer. Next,
glycoproteins were released from the virus by bromelain (Sigma-
Aldrich) digestion for 1 hour at 37uC and digested viruses were
pelleted by centrifugation at 55.000 rpm for 10 minutes. A
protease inhibitor tablet was added to the NA containing
supernatant to prevent further protein degradation (Roche). NA
was purified by layering the supernatant over a sucrose gradient
(5–25% sucrose in 10 mM TRIS buffer (pH 8.0) and centrifuga-
tion at 38000 rpm for 18 hours at 4uC. Subsequently, NA-
containing fractions were pooled and further purified using an Q-
15 anion-exchange column (Sartorius). Finally, buffer was changed
by overnight dialysis against Tris-buffer supplemented with 5 mM
CaCl2 and neuraminidase protein was concentrated 6 mg/ml
using a 50 kD vivaspin column (Sartorius) for crystallization
experiments.
Protein crystallography
Neuraminidase crystals were obtained by vapor diffusion from
sitting drops dispensed with an Oryx 8 robot (Douglas Instru-
ments). The drops consisted of 100 nl of protein in the absence or
presence of 1 mM inhibitor (oseltamivir or zanamivir) mixed with
100 nl of reservoir solution. The reservoir solution of the I223R
ligand-free crystal consisted of 20% PEG1000, 0.6 M Ammonium
Phosphate and 0.1 M Sodium Acetate (pH 4.6). The reservoir
solution of the I223R crystal in complex with zanamivir consisted
of 18% PEG3350, 0.2 M Sodium Fluoride and 0.1 M bis-TRIS
Propane buffer (pH 6.5). The reservoir solutions of the other
crystals consisted of 15% PEG3350, 0.1 M bis-TRIS propane and
0.1 M sodium acetate buffer (pH 4.6). Crystals were transferred
into a cryoprotectant that consisted of reservoir solution supple-
mented with 20% (v/v) ethylene glycol before flash freezing in
liquid nitrogen. Data sets were recorded on an ADSC Q315 CCD,
Pilatus 6M-F and SLS/Dectris Pilatus miniCBF detectors at the
Diamond light source (Oxford, UK). Diffraction images were
integrated using iMOSLFM [35] or DENZO and scaled with
SCALA [36] or SCALEPACK for the ligand-free I223R structure.
Neuraminidase structures were solved by molecular replacement
with PHASER [37] using the wild type structure (protein databank
(PDB) identification (ID) code 2HU4) as the initial search model.
Refinement was performed using Refmac5 [38] or PHENIX
Refine [39]. Manual model building was done using Coot [40],
structure validation was assessed with MOLPROBIDITY [41]
and figures were created using Pymol (http://pymol.sourceforge.
net/).
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